Diabetes mellitus is the most common cause of chronic renal failure in the world. Diabetic nephropathy is a disease characterized by persistent proteinuria, decreased glomerular filtration rate (GF), blood pressure and progression to the final stage of kidney failure. Hypertension is common in patients with chronic kidney disease (CKD) and diabetes. In this population, hypertension increases the risk of kidney disease and progression of cardiovascular (CV) morbidity and mortality. Diabetic nephropathy (DN) is the most common cause of CKD in patients with diabetes. The mechanism of hypertension, diabetic nephropathy is complex and insufficiently understood, and includes the excess sodium retention, sympathetic nervous system (SNS) and the activation of Irene - angiotensin - aldosterone system (RAAS) system, dysfunction of the endothelium - muscle cells. These mechanisms are responsible for the development and aggravation of hypertension in this population and have contributed to the increased risk of adverse CV outcome. Current management of hypertension in diabetic nephropathy should include therapies that block the production or action of angiotensin and blood pressure treatment goals with these drugs should be focused on blood pressure < 130/80 mmHg. Important to the achievement of this goal will be necessary to use both non - pharmacological intervention in combination with more antihypertensive drugs. Recent studies investigating the use of combination therapy using more than one drug RAAS, and formal recommendations await their results.